Khazdooz Hamid, Abbasian Ladan, Shirzad Nooshin, Khashayar Pouria, SeyedAlinaghi SeyedAhmad, Malekahmadi Mahsa, Hemmatabadi Mahboobeh
Department of Endocrinology, Vali-Asr Hospital, Endocrinology, and Metabolism Research Centre, Imam Khomeini Complex Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Department of Infectious Diseases, Iranian Research Center for HIV/AIDS (IRCH), Iranian institute for Reduction of High Risk Behaviors, Imam Khomeini Complex Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Curr HIV Res. 2025;23(2):77-84. doi: 10.2174/011570162X340090250204072449.
The increased risk ofmetabolic syndrome (MetS) and its subcomponents among people living with HIV/AIDS, especially in developing countries, is well documented with the global pooled prevalence of the related risk factors in this population.
This study aimed to explore the prevalence of MetS among Iranian People living with HIV according to the ATP III and Iranian criteria.
The cross-sectional study was conducted on consecutive patients who visited THE referral centre for AIDS/HIV between May to December 2023. A total of 130 participants (n=83; 63.8%male) were investigated based on the inclusion criteria, which included having a minimum age of 25 and a maximum of 65 years and following a stable ART treatment regimen for at least six months. A Chi-square test was used to determine the relationship between the categorical variables. Uni/Multi-variable linear regression analysis was used to quantify the associations between MetS and HIV by the independent variables.
The incidence of MetS according to ATP III and Iranian criteria were 42 (32.3%) and 45 (34.6%), which was higher in older patients (p=0.001) and those with more duration since HIV diagnosis (p=0.02). Around 33.1% and 16.1% were overweight and obese, respectively. Among the components of MetS, the highest prevalence (50.8%) was related to low HDL, and the lowest was related to fasting blood sugar (21.5%). The average body fat mass, protein mass, Soft lean mass, and percentage body fat were 18.54 ± 9.46 kg, 10.91 ± 2.17 kg, 51.31 ± 9.61 kg, and 24.86±10.25% that were higher in MetS group (p<0.05).
Our study points out the high prevalence of MetS in an Iranian population living with HIV, especially those suffering from the underlying disease for a longer time. Conducting multi-centric studies with larger sample sizes is needed to confirm our results and determine the most effective measures.
有充分文献记载，在艾滋病毒/艾滋病感染者中，代谢综合征（MetS）及其亚组分的风险增加，尤其是在发展中国家，该人群中相关风险因素的全球汇总患病率也表明了这一点。
本研究旨在根据ATP III和伊朗标准，探讨伊朗艾滋病毒感染者中代谢综合征的患病率。
本横断面研究针对2023年5月至12月期间前往艾滋病/艾滋病毒转诊中心就诊的连续患者进行。共有130名参与者（n = 83；63.8%为男性）根据纳入标准接受调查，纳入标准包括年龄最小25岁、最大65岁，且至少接受稳定抗逆转录病毒治疗方案六个月。采用卡方检验确定分类变量之间的关系。单/多变量线性回归分析用于通过自变量量化代谢综合征与艾滋病毒之间的关联。
根据ATP III和伊朗标准，代谢综合征的发病率分别为42例（32.3%）和45例（34.6%），老年患者（p = 0.001）以及自艾滋病毒诊断以来病程较长的患者（p = 0.02）发病率更高。超重和肥胖者分别约占33.1%和16.1%。在代谢综合征的组分中，患病率最高的是高密度脂蛋白降低（50.8%），最低的是空腹血糖（21.5%）。代谢综合征组的平均体脂质量、蛋白质质量、瘦软组织质量和体脂百分比分别为18.54±9.46千克、10.91±2.17千克、51.31±9.61千克和24.86±10.25%，均较高（p < 0.05）。
我们的研究指出，伊朗艾滋病毒感染者中代谢综合征的患病率较高，尤其是那些患有基础疾病时间较长的患者。需要开展更大样本量的多中心研究来证实我们的结果并确定最有效的措施。
